good one! I don't follow the company but the CEO sounds like a straight shooter. However he also didn't say the preclinical signal was not there for the second generation so I still think it would have been worth an ask, but it could have been implied. Regardless they have clean data on the 75 patients that have already received LNP2 which bodes well (and yes I assume these patients had the identical delivery w liver targeting moiety but it wasn't expressly stated IIRC) good luck!
News 
Market Data 
Discover 
